NovoCure：為何我看淡第二季財報引發的漲勢 (NASDAQ:NVCR)
· seekingalpha.com
NovoCure 股票維持「持有」評級：第二季營收成長 16% 且 EBITDA 指引有所改善，但現金生成能力依舊落後。點擊閱讀我的分析。
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions...